ANGO
Angiodynamics Inc
$14.47
+1.47 (+11.31%)
At close · Jul 15
Market Cap
$604.69M
Shares
41,332,389
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.47
Open$13.09
Day$12.85–14.80
52W$8.36–14.80
Avg vol 30d443K
Short int1.4M · 3.3% float · 2.9d
Short vol16%
Last earningsJul 14, 2026
DataJan 2020–Jul 2026
Filing10-K · Jul 14
Up next
Next earnings call
Oct 13, 2026
Est · unconfirmed
· in 13 wks
FQ1-27 quarter ends
~Aug 31, 2026
Est
filed Jul 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
+20%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+37%
trailing
YTD return
+13%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Distributing
7 of 146 funds reported for Jun 30 · net -19.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.28% of float · ▼ -22.7% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
146 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
60%
expanding
EPS growth
−6%
Y/Y
Free cash flow
$508.0K
Buyback
$13.3M
remaining
Balance sheet
$53.9M
net cash
Quant / Vol
risk profile
Volatility
43%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
+20%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Distributing
7 of 146 funds reported for Jun 30 · net -19.7K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.28% of float · ▼ -22.7% MoM · 2.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
146 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $8
Now $14 · 95%
52-wk high $15
vs 200-day avg +25%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $13.2M | Year Ended May 31, 2026 | — |
|
|
|||
| Mechanical thrombectomy full year growth | 13.4% | FY2026 call | — |
| Med device segment year-over-year growth | 1.1% | Q4 FY2026 call | — |
| MedTech platforms share of total revenue | 48% | Q4 FY2026 call | — |
|
|
|||
| NanoKnife capital sales growth | 132.5% | Q4 FY2026 call | — |
| NanoKnife probe revenue growth | 47% | Q4 FY2026 call | — |
| Adjusted loss per share non-GAAP | -$0.07 | Q3 FY2026 | — |
| Auryon sales | $16.3M | Q3 FY2026 | — |
| Mechanical Thrombectomy sales | $11.5M | Q3 FY2026 | — |
| Med Device Net Sales | $41.1M | Q3 FY2026 | — |
| Med Tech Net Sales | $37.3M | Q3 FY2026 | — |
| NanoKnife sales | $7.6M | Q3 FY2026 | — |
| Alphavac revenue | $4.4M | Q3 FY2026 call | — |
| Alphavac year-over-year growth | 47.4% | Q3 FY2026 call | — |
| AngioVac revenue | $7.2M | Q3 FY2026 call | — |
| AngioVac year-over-year growth | 5% | Q3 FY2026 call | — |
| Arian platform revenue | $16.3M | Q3 FY2026 call | — |
| Arian platform year-over-year growth | 17.9% | Q3 FY2026 call | — |
| Mechanical thrombectomy revenue | $11.5M | Q3 FY2026 call | — |
| Mechanical thrombectomy year-over-year growth | 17.9% | Q3 FY2026 call | — |
| MedDevice segment year-over-year growth | 1.1% | Q3 FY2026 call | — |
| MedDevice segment year-to-date growth | 3% | Year-to-date FY2026 call | — |
| MedTech revenue | $37.3M | Q3 FY2026 call | — |
| MedTech segment year-to-date growth | 19.1% | Year-to-date FY2026 call | — |
| NanoKnife capital sales year-over-year growth | 24.9% | Q3 FY2026 call | — |
| NanoKnife probes year-over-year growth | 20% | Q3 FY2026 call | — |
| NanoKnife revenue | $7.6M | Q3 FY2026 call | — |
| NanoKnife revenue year-over-year growth | 21% | Q3 FY2026 call | — |
| Tariff expense | $1.3M | Q3 FY2026 call | — |
| Med Device Pro Forma YoY Growth | 5.6% | Q2 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANGO
this stock
Angiodynamics Inc
|
$604.69M | +12.7% | +10.2% | — | 3.3% |
|
ISRG
Intuitive Surgical Inc
|
$137.76B | -31.3% | +20.5% | 47.3 | 2.1% |
|
MDLN
Medline Inc.
|
$51.65B | -6.1% | +11.5% | — | 2.8% |
|
BDX
Becton Dickinson & Co
|
$42.68B | +2.9% | +8.2% | 58.9 | 4.1% |
|
ALC
Alcon Inc
|
$33.40B | -13.1% | +10.5% | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANGO | +13.0% | +20.4% | +36.9% | +11.2% | +12.7% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +11.7% | +20.6% | +26.8% | +10.1% | +2.0% |
Capital returns
Buyback program
· as of May 31, 2026
Authorized
$15.00M
Spent (derived)
$1.70M
Remaining
$13.30M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.